Table 3:
Proportions of patients who discontinued, down-titrated, stabilized and up-titrated their RAASi therapy post-index versus pre-index in the USA, Japan and Spain.
| Overall | SZC | No K+ binder | P-value |
|---|---|---|---|
| USA | n = 565 | n = 2068 | |
| Discontinued | 112 (19.8) | 727 (35.2) | <.0001 |
| Down-titrated | 64 (11.3) | 243 (11.8) | .8386 |
| Stabilized | 327 (57.9) | 976 (47.2) | <.0001 |
| Up-titrated | 62 (11.0) | 122 (5.9) | <.0001 |
| Japan | n = 776 | n = 2629 | |
| Discontinued | 72 (9.3) | 926 (35.2) | <.0001 |
| Down-titrated | 84 (10.8) | 232 (8.8) | .1059 |
| Stabilized | 536 (69.1) | 1283 (48.8) | <.0001 |
| Up-titrated | 84 (10.8) | 188 (7.2) | .0012 |
| Spain | n = 56 | n = 203 | |
| Discontinued | 10 (17.9) | 73 (36.0) | .0102 |
| Down-titrated | 7 (12.5) | 32 (15.8) | .5455 |
| Stabilized | 33 (58.9) | 63 (31.0) | .0001 |
| Up-titrated | 6 (10.7) | 35 (17.2) | .2362 |
Values are presented as n (%).
P-values for differences between the SZC cohort versus the no K+ binder cohort in the proportions of patients who discontinued, down-titrated, stabilized and up-titrated their RAASi therapy at 180 days post-index versus pre-index were calculated using the χ2 test.